# Lapam Capital

> Lapam Capital is a VC fund in Beijing backing Biotechnology and Pharmaceutical. See 44 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 44
- Last investment: May 2026
- Lead investor: 41%
- Last updated: Aug 2026
- Website: http://lapamcapital.com/

Lapam Capital is a healthcare-focused venture capital firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $13M–$40M |
| Series B | $20M–$82M |
| Series C | $14M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 26 | 59% |
| Pharmaceutical | 14 | 32% |
| Health Care | 11 | 25% |
| Medical | 10 | 23% |
| Biopharma | 5 | 11% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 13 | 30% |
| Series B | 11 | 25% |
| Series C | 8 | 18% |
| Seed | 2 | 5% |
| Angel | 1 | 2% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 27 | 61% |
| United States | 5 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $40M | Series A | May 14, 2026 |  |
| NeuShen Therapeutics | NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. |  | Series A | Jan 28, 2026 |  |
| Lingtai Biotechnology | Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs. | $28.4M | Series B | Dec 18, 2025 |  |
| Allink Biotherapeutics | Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment. | $47M | Series A | Dec 16, 2025 |  |
| BridGene Biosciences | BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $28M | Series B | Oct 16, 2025 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $50M | Series C | Sep 29, 2025 |  |
| Epigenic Therapeutics | Epigenic Therapeutics is a biotech firm that offers gene editing therapy. | $60M | Series B | Sep 07, 2025 |  |
| Rapafusyn Pharmaceuticals | Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M | Series A | Sep 04, 2025 |  |
| LTZ Therapeutics | LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need. | $40M | Series A | Apr 24, 2025 |  |
| Enchannel | Enchannel Medical is a global innovation platform that focuses on electrophysiology and provides atrial fibrillation treatment solution around "3D mapping + PFA ablation". | $82.3M | Series B | Apr 23, 2025 |  |

10 of 44 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 6 deals together
- [Prox Ventures](https://shizune.co/investors/profile/prox-ventures) — VC Fund, 5 deals together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 4 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 3 deals together
- [Cowin Capital](https://shizune.co/investors/profile/cowin-capital) — VC Fund, 3 deals together
- [Dyee Capital](https://shizune.co/investors/profile/dyee-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Asia](https://shizune.co/investors/biotechnology-investors-asia)
- [Biotechnology VC Funds in Asia](https://shizune.co/investors/biotechnology-vc-funds-asia)
- [Biotechnology Investors in China](https://shizune.co/investors/biotechnology-investors-china)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech Investors in Asia](https://shizune.co/investors/biotech-investors-asia)
- [Biotech VC Funds in Asia](https://shizune.co/investors/biotech-vc-funds-asia)

## FAQ

### What does Lapam Capital invest in?

Lapam Capital invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Lapam Capital's check size?

Lapam Capital typically joins rounds of $13M–$40M at Series A, $20M–$82M at Series B and $14M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lapam Capital participates in.

### When did Lapam Capital last invest?

The most recent investment recorded for Lapam Capital closed in May 2026. Shizune tracks 44 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co